CJC-1295 with DAC carries an albumin-binding modification on top of the base GHRH-fragment sequence, and verifying both the fragment and the modification are correctly present is the point of lot-level testing.
Reversed-phase HPLC
HPLC separates the DAC-modified peptide from unmodified fragment, partially reacted intermediates, and other synthesis byproducts, with purity read per understanding HPLC purity.
Mass spectrometry for identity
Because the DAC modification adds measurable mass relative to the no-DAC form, mass spectrometry can confirm not just that a peptide is present but that the albumin-binding modification described in the chemistry article is actually attached — see HPLC vs. mass spectrometry.
Why this matters for a long-acting research tool
DAC CJC-1295's extended research half-life depends entirely on the modification being intact; an incompletely reacted or degraded lot could behave more like the shorter-acting no-DAC form without that being obvious from appearance alone.
Documentation to expect
A lot-specific certificate of analysis with HPLC purity and mass-spec identity — see how to read a CoA.
Product page: CJC-1295 (DAC) research vials.
Research Use Only. Supplied strictly for laboratory research and development — not for human or veterinary use, consumption, or any therapeutic or diagnostic purpose. This article is research education, not usage guidance.